Recommendation of the advisory committee on immunization practices (ACIP) for use of quadrivalent meningococcal conjugate vaccine (MenACWY-D) among children aged 9 through 23 months at increased risk for invasive meningococcal disease

Morbidity and Mortality Weekly Report

Volumn 60, Issue 40, 2011, Pages 1391-1392

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G; MENACWY D VACCINE; MENACWY-D VACCINE; MENINGOCOCCUS VACCINE;

ANTIBODY PRODUCTION; ARTICLE; HUMAN; IMMUNIZATION; IMMUNOLOGY; INFANT; MENINGOCOCCOSIS; PRACTICE GUIDELINE; RISK FACTOR;

ANTIBODY FORMATION; HUMANS; IMMUNIZATION SCHEDULE; IMMUNOGLOBULIN G; INFANT; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; RISK FACTORS;

EID: 80054794075     PISSN: 01492195     EISSN: 1545861X     Source Type: Journal    
DOI: None     Document Type: Article

References (6)

1. Food and Drug Administration. April 22, 2011 approval letter---Menactra. Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration; 2011. Available at http://www.fda.gov/biologicsbloodvaccines/vaccines/approvedproducts/ucm252511.htm. Accessed October 4, 2011.
2. CDC. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2005;54(No. RR-7).
3. Food and Drug Administration. Product approval information: package insert. Menactra (meningococcal (groups A, C, Y and W-135) polysaccharide diphtheria toxoid conjugate vaccine). Sanofi Pasteur. Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration; 2011. Available at http://www.fda.gov/downloads/biologicsbloodvaccines/vaccines/approvedproducts/ucm131170.pdfAccessed October 4, 2011.
4. Johnson DR. Menactra infant indication; meningococcal (groups A, C, Y and W-135) polysaccharide diphtheria toxoid conjugate vaccine. Presented at the meeting of the Advisory Committee on Immunization Practices, Atlanta, GA, June 22, 2011.
5. CDC. Recommendation from the Advisory Committee on Immunization Practices (ACIP) for use of quadrivalent meningococcal conjugate vaccine (MCV4) in children aged 2-10 years at increased risk for invasive meningococcal disease. MMWR 2007;56:1265-6.
6. CDC. Updated recommendation from the Advisory Committee on Immunization Practices (ACIP) for revaccination of persons at prolonged increased risk for meningococcal disease. MMWR 2009;58:1042-3.